CAR-T cell therapy for relapsed or refractory acute myeloid leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new type of cell therapy called CAR-T, which uses specially engineered immune cells to target acute myeloid leukemia (AML) that hasn't responded to standard treatment. The goal is to see if this therapy can help patients whose cancer has come back or stopped responding to chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–70 years old
- Diagnosed with relapsed or refractory AML (cancer that came back or didn't respond to treatment) with a specific marker called NKG2D ligand
- Bone marrow showing at least 5% blast cells (immature blood cells)
- Expected to live at least 12 more weeks
- Good heart, liver, kidney, and blood-clotting function without needing ongoing support
- No previous CAR-T therapy, stem cell transplant in the past 3 months, or active uncontrolled infection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational therapy (CT1390B) for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. It aims to see if the therapy is safe and helps patients with a specific marker called CLL-1.
This trial tests a new type of CAR-T cell therapy that targets two proteins on leukemia cells (called CLL1 and CD33). The goal is to help people with acute myeloid leukemia that has relapsed or not responded to standard treatments.
This trial tests a new type of cell therapy, called CAR-T, that uses your own immune cells to find and attack leukemia cells. It's designed for people whose AML has come back or hasn't responded to standard treatments. The cells are modified to target a protein called CD33 on leukemia cells.
This study tests a new treatment made from your own immune cells, engineered to find and attack AML cells. It is for patients whose leukemia has not responded to standard therapy or has come back after treatment, including after a stem cell transplant.
This trial tests a new type of cell therapy called NKG2D CAR-T for people with AML that has not responded to standard treatment or has come back. It aims to use your own immune cells, modified to attack the leukemia, to help you achieve remission.
This trial tests a new treatment that uses your own immune cells, modified in the lab to find and attack leukemia cells. It's for people with AML that has come back or hasn't responded to standard treatment, and it may be followed by a stem cell transplant to help prevent the cancer from returning.
Hear when a new AML trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.